Alembic Ltd

Alembic Pharmaceuticals recently announced its financial results for Q3 FY24-25, highlighting a significant year-on-year growth in Profit Before Tax and net sales, both reaching their highest levels in five quarters. The half-year Profit After Tax also showed notable growth, reflecting the company's strong performance in the sector.

Alembic Pharmaceuticals has experienced a revision in its score by MarketsMOJO, reflecting recent performance metrics. Despite a notable increase in net sales and consistent quarterly profits, the stock's evaluation has been adjusted. The company remains in a stable financial position, supported by a low debt-to-equity ratio and increased institutional investment.

Alembic has recently experienced a revision in its score, reflecting the company's robust financial performance and positive market indicators. With a notable increase in net sales and strong institutional interest, Alembic has been added to MarketsMOJO's list, highlighting its potential as a compelling investment opportunity.

Alembic has experienced a notable rise in its stock performance, prompting a revision in its score by MarketsMOJO. The stock has consistently outperformed the sector and major indices, indicating strong market positioning and potential for continued growth. Investors are encouraged to monitor this smallcap pharmaceutical company closely. On December 11, 2024, Alembic's stock gained significantly, reflecting a positive trend over the past few days. The stock has surpassed its moving averages across multiple timeframes, showcasing robust performance indicators. With its recent addition to MarketsMOJO's list, Alembic is positioned as a noteworthy option for investors seeking growth opportunities.

Alembic, a smallcap pharmaceutical company, has reported a positive financial performance in the quarter ending September 2024. The company's PBT less Other Income has increased by 98.90% year on year, while Net Sales have seen a 63.91% increase. However, the company's high reliance on non-business activities and sustainability of its increased income may be a concern for investors.

On November 11, 2024, Alembic, a smallcap pharmaceutical company, experienced a 7.86% increase in its stock price, outperforming the sector by 7.56%. This follows two days of declining prices, suggesting a potential trend reversal. According to MarketsMOJO, the stock is currently rated as 'Hold', based on its strong performance and market trends, without any external influence. Alembic has consistently outperformed the market and has shown a strong upward trend, making it a promising choice for investors.

Alembic, a smallcap pharmaceutical company, has reached a new milestone as its stock price hit a 52-week high on August 23, 2024. According to MarketsMOJO, the stock has been given a 'Hold' rating and has consistently outperformed the sector. It has also shown a consecutive gain for the past 3 days and is currently trading higher than its moving averages. With a 1-year performance of 109.71%, Alembic is a strong player in the market.

On August 22, 2024, Alembic, a smallcap pharmaceutical company, saw a 7.45% increase in its stock price, closing at Rs.162.9, its new 52-week and all-time high. According to MarketsMOJO, the stock call for Alembic is 'Hold', based on its recent performance and market trends. The stock has been on a consecutive rise in the last two days, currently trading higher than its moving averages and outperforming the Sensex. Investors are advised to do their own research before investing.

Alembic, a smallcap pharmaceutical company, has reached a 52-week high on August 22, 2024, with its stock price surging to Rs.160. The stock has been performing well, outperforming the sector by 5.59% and showing consecutive gains for the past 2 days. Alembic's stock is trading higher than its moving averages, indicating a positive trend. Its impressive growth of 100.30% in the past year highlights its potential in the pharmaceutical industry.

Alembic, a smallcap pharmaceutical company, has announced its financial results for the quarter ending March 2024. With a score of 15, an improvement from the previous quarter, the company has shown positive performance. Key factors include a 95.18% increase in PBT and highest net sales in five quarters. PAT has also grown by 25.8%.

Alembic, a smallcap pharmaceutical company, has reached a new milestone as its stock price hit a 52-week high on July 26, 2024. According to MarketsMOJO, the stock is currently rated as 'Hold' but has been consistently outperforming the sector by 1.65%. With consecutive gains and trading above its moving averages, Alembic has shown an impressive 104.34% increase in the past year, solidifying its position as a strong player in the industry.

Alembic, a smallcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on July 16, 2024. According to MarketsMOJO, the current stock call for Alembic is 'Hold', with the stock consistently gaining in the past three days and trading higher than its moving averages. The company's impressive growth of 101.23% in the past year highlights its strong position in the industry, driven by its focus on innovation and quality.

Alembic, a smallcap pharmaceutical company, has reached a 52-week high on July 15, 2024, with a 'Hold' call from MarketsMOJO. The stock has shown consecutive gains for the past two days, outperforming the sector by 3.16%. It has consistently traded above its moving averages, showcasing a positive trend. With a remarkable growth of 94.93% in the past year, Alembic has proven to be a strong player in the market with a promising future in the pharmaceutical industry.

On July 12, 2024, Alembic, a smallcap pharmaceutical company, saw a 7.01% increase in its stock price, reaching a new 52-week and all-time high of Rs.148.65. This rise was in line with the overall positive trend in the market, with the stock outperforming the sector by 6.98%. According to MarketsMOJO, the current recommendation for Alembic's stock is 'Hold', based on the company's performance and market trends. Despite high volatility on the day of the price increase, the stock remained above its moving averages, indicating a positive trend. In comparison to the overall market performance, Alembic's stock has shown a strong 1-day and 1-month performance, making it a promising investment option.

Alembic, a smallcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on July 12, 2024. With a 'Hold' rating from MarketsMOJO, the stock is currently trading at Rs 143.65, outperforming the sector by 3.87%. It has also shown a positive trend in the short and long term, with a strong performance compared to the Sensex. Investors should conduct their own research before investing.

Alembic, a leading pharmaceutical company in the smallcap industry, reached a new milestone as its stock price hit a 52-week high on July 10, 2024. The stock's current rating is 'Hold' according to MarketsMOJO, with a consecutive 4-day gain of 19.58%. Its trading price is above all moving averages, indicating a positive trend and potential for further growth. Compared to the Sensex, Alembic has shown a remarkable 1-year performance of 95.51%, highlighting its strong performance and potential for future growth.

Alembic, a leading pharmaceutical company, has reached a 52-week high on July 9th, 2024, gaining attention from investors and market analysts. With a current stock call of 'Hold' by MarketsMOJO, Alembic has outperformed the sector by 1.71% and seen a 14.56% rise in the last 3 days. Its impressive 84.14% increase in the past year and positive trend in trading indicate a strong position in the pharma industry. This success can be attributed to its strong product portfolio and focus on research and development, making Alembic a promising stock in the smallcap industry.

On July 8th, 2024, Alembic, a smallcap pharmaceutical company, saw a 7.4% increase in its stock price, hitting a new 52-week high. This rise can be attributed to the company's strong performance in the market, with a 'Hold' rating from financial analysis firm MarketsMOJO. Alembic's stock has outperformed the sector and is currently trading above its moving averages, indicating a positive trend.

Alembic, a smallcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on July 8th, 2024. With consecutive gains for the past 2 days and consistently trading higher than its moving averages, the stock has shown a remarkable growth of 69.67% in the past year, outperforming the Sensex.